Loading...
OTCMCLPBF
Market cap24bUSD
Dec 13, Last price  
112.54USD
Name

Coloplast A/S

Chart & Performance

D1W1MN
OTCM:CLPBF chart
P/E
37.64
P/S
7.35
EPS
21.44
Div Yield, %
16.92%
Shrs. gr., 5y
Rev. gr., 5y
8.29%
Revenues
27.03b
+10.33%
6,232,000,0006,709,000,0008,042,000,0008,463,000,0008,820,000,0009,537,000,00010,172,000,00011,023,000,00011,635,000,00012,428,000,00013,909,000,00014,681,000,00015,528,000,00016,449,000,00017,939,000,00018,544,000,00019,426,000,00022,579,000,00024,500,000,00027,030,000,000
Net income
5.05b
+5.62%
553,000,000466,000,000370,000,000715,000,000883,000,0001,243,000,0001,819,000,0002,194,000,0002,711,000,0002,390,000,000899,000,0003,143,000,0003,797,000,0003,845,000,0003,873,000,0004,197,000,0004,825,000,0004,706,000,0004,783,000,0005,052,000,000
CFO
2.77b
-34.55%
1,353,000,000966,000,0001,004,000,0001,324,000,0001,830,000,0001,769,000,0002,205,000,0002,649,000,0003,136,000,0003,149,000,0003,337,000,0003,028,000,0003,251,000,0004,361,000,0004,357,000,0004,759,000,0005,290,000,0005,099,000,0004,226,000,0002,766,000,000
Dividend
May 13, 20240.72234 USD/sh
Earnings
Feb 07, 2025

Profile

Coloplast A/S develops and sells intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Interventional Urology, Voice and Respiratory Care, and Wound & Skin Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, it offers voice and respiratory products, including medical devices for neck stoma under the Provox brand; and products for tracheostoma under the TRACOE brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.
IPO date
Jan 01, 1983
Employees
14,700
Domiciled in
DK
Incorporated in
DK

Valuation

Title
DKK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑092023‑092022‑092021‑092020‑092019‑092018‑092017‑092016‑092015‑09
Income
Revenues
27,030,000
10.33%
24,500,000
8.51%
22,579,000
16.23%
Cost of revenue
20,480,000
17,677,000
15,718,000
Unusual Expense (Income)
NOPBT
6,550,000
6,823,000
6,861,000
NOPBT Margin
24.23%
27.85%
30.39%
Operating Taxes
1,343,000
1,242,000
1,421,000
Tax Rate
20.50%
18.20%
20.71%
NOPAT
5,207,000
5,581,000
5,440,000
Net income
5,052,000
5.62%
4,783,000
1.64%
4,706,000
-2.47%
Dividends
(4,720,000)
(4,247,000)
(4,041,000)
Dividend yield
2.40%
2.64%
2.45%
Proceeds from repurchase of equity
500,000
9,134,000
(619,000)
BB yield
-0.25%
-5.67%
0.37%
Debt
Debt current
5,338,000
7,345,000
1,853,000
Long-term debt
18,278,000
13,116,000
17,560,000
Deferred revenue
199,000
Other long-term liabilities
155,000
6,000
396,000
Net debt
22,726,000
19,446,000
18,948,000
Cash flow
Cash from operating activities
2,766,000
4,226,000
5,099,000
CAPEX
(1,346,000)
(1,241,000)
(1,135,000)
Cash from investing activities
(1,336,000)
(8,957,000)
(11,759,000)
Cash from financing activities
(1,518,000)
5,265,000
6,591,000
FCF
(9,062,000)
14,539,000
(297,000)
Balance
Cash
788,000
911,000
633,000
Long term investments
102,000
104,000
(168,000)
Excess cash
Stockholders' equity
17,942,000
14,860,000
5,602,000
Invested Capital
40,726,000
29,400,000
26,054,000
ROIC
14.85%
20.13%
29.96%
ROCE
15.16%
21.65%
24.39%
EV
Common stock shares outstanding
224,900
215,500
212,800
Price
875.00
17.04%
747.60
-3.63%
775.80
-22.92%
Market cap
196,787,500
22.15%
161,107,800
-2.41%
165,090,240
-23.07%
EV
219,513,500
181,709,800
184,533,240
EBITDA
7,840,000
7,892,000
7,791,000
EV/EBITDA
28.00
23.02
23.69
Interest
882,000
638,000
172,000
Interest/NOPBT
13.47%
9.35%
2.51%